
News|Articles|July 1, 2003
Lescol and Lescol XL (Fluvastatin) Novartis
Statin indicated for reduction in the risk of recurrent cardiac events
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
What employees may miss when they buy drugs directly online
5





















